Skip to main content
. Author manuscript; available in PMC: 2015 Jun 5.
Published in final edited form as: Mol Cancer Ther. 2008 May;7(5):1275–1284. doi: 10.1158/1535-7163.MCT-07-2043

Figure 6.

Figure 6

Development of macroscopic BCCs and SpCTs. A, tazarotene (n = 26) and the RXR agonist (n = 7) were the most effective at inhibiting macroscopic BCC development followed by the RARα agonist (n = 20) and ATRA (n = 13). The RAR antagonist significantly increased the number of macroscopic BCC tumors (n = 19) compared with vehicle. B, tazarotene and the RXR agonist were the most effective at inhibiting macroscopic SpCT development followed by ATRA. Treatment with the RARα agonist appeared to increase the number of macroscopic SpCTs. The RAR antagonist did not significantly affect the number SpCT compared with vehicle. *, P < 0.05; **, P < 0.01; ***, P < 0.0001.